GleamWall
中文EN

ZBIO Zenas BioPharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1953926 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-185.3%
TTM EPS YoY-173.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-265.1%
ROA-108.7%
ROIC (approx.)-441.5%
Asset turnover—

Leverage & solvency

Liabilities / assets68.6%
Debt / equity0.00x
Current ratio9.42x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.45x
Accruals ratio-60.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$10.00M$5.00M
R&D expense$168.06M$139.14M
SG&A expense$53.32M$29.75M
Operating income-$383.06M-$163.89M
Interest expense$7.33M—
Pretax income-$377.82M-$156.56M
Income tax-$79,000$429,000
Net income-$377.74M-$156.99M
EBITDA-$383.00M-$163.75M
EPS (basic)-8.44-11.89
EPS (diluted)-8.44-11.89
Weighted avg. shares (diluted)44.73M13.20M
Balance sheet
Cash & equivalents$110.64M$319.83M
Short-term investments$232.55M$31.02M
Current assets$351.17M$355.92M
PP&E, net$34,000$185,000
Total assets$383.64M$369.97M
Current liabilities$62.65M$57.29M
Long-term debt$78.64M—
Total debt$78.64M—
Total liabilities$141.50M$57.51M
Shareholders' equity$242.14M$312.46M
Net debt-$32.01M—
Shares outstanding54.49M41.79M
Cash flow statement
Operating cash flow-$172.33M-$119.67M
Capital expenditure$18,000$131,000
Free cash flow-$172.35M-$119.81M
Investing cash flow-$251.89M-$30.55M
Financing cash flow$215.28M$412.96M
Depreciation & amortization$56,000$137,000
Stock-based compensation$26.35M$10.82M

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.